Consulting Services
Compare Stocks
4 / 10Stock Comparison
SBC vs LASE vs NPKI vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Oil & Gas Equipment & Services
Household & Personal Products
SBC vs LASE vs NPKI vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Consulting Services | Industrial - Machinery | Oil & Gas Equipment & Services | Household & Personal Products |
| Market Cap | $329M | $16M | $1.30B | $118M |
| Revenue (TTM) | $178M | $7M | $287M | $296M |
| Net Income (TTM) | $43M | $-8M | $36M | $-6M |
| Gross Margin | 73.7% | 31.1% | 35.2% | 64.9% |
| Operating Margin | 33.3% | -126.5% | 11.4% | -3.6% |
| Forward P/E | 7.1x | — | 29.3x | — |
| Total Debt | $12M | $5M | $37M | $379M |
| Cash & Equiv. | $125M | $534K | $5M | $233M |
SBC vs LASE vs NPKI vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | May 26 | Return |
|---|---|---|---|
| SBC Medical Group H… (SBC) | 100 | 44.4 | -55.6% |
| Laser Photonics Cor… (LASE) | 100 | 12.9 | -87.1% |
| NPK International I… (NPKI) | 100 | 184.6 | +84.6% |
| The Beauty Health C… (SKIN) | 100 | 61.5 | -38.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBC vs LASE vs NPKI vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SBC carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.76, Low D/E 6.3%, current ratio 3.01x
- Beta 0.76, current ratio 3.01x
- Lower P/E (7.1x vs 29.3x)
- 24.3% margin vs LASE's -105.4%
LASE is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 1.68
NPKI is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 27.4%, EPS growth 124.0%, 3Y rev CAGR 12.8%
- 91.5% 10Y total return vs SBC's -67.8%
- 27.4% revenue growth vs LASE's -13.3%
- +94.9% vs LASE's -74.1%
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.4% revenue growth vs LASE's -13.3% | |
| Value | Lower P/E (7.1x vs 29.3x) | |
| Quality / Margins | 24.3% margin vs LASE's -105.4% | |
| Stability / Safety | Beta 0.76 vs SKIN's 2.00, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +94.9% vs LASE's -74.1% | |
| Efficiency (ROA) | 13.5% ROA vs LASE's -43.1%, ROIC 72.3% vs -42.1% |
SBC vs LASE vs NPKI vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SBC vs LASE vs NPKI vs SKIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SBC leads in 2 of 6 categories
SKIN leads 1 • NPKI leads 1 • LASE leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SBC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SKIN is the larger business by revenue, generating $296M annually — 41.5x LASE's $7M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to LASE's -105.4%. On growth, LASE holds the edge at +28.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $178M | $7M | $287M | $296M |
| EBITDAEarnings before interest/tax | $62M | -$8M | $53M | $9M |
| Net IncomeAfter-tax profit | $43M | -$8M | $36M | -$6M |
| Free Cash FlowCash after capex | -$37M | -$4M | $32M | $29M |
| Gross MarginGross profit ÷ Revenue | +73.7% | +31.1% | +35.2% | +64.9% |
| Operating MarginEBIT ÷ Revenue | +33.3% | -126.5% | +11.4% | -3.6% |
| Net MarginNet income ÷ Revenue | +24.3% | -105.4% | +12.4% | -2.0% |
| FCF MarginFCF ÷ Revenue | -20.5% | -58.7% | +11.1% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.3% | +28.3% | +15.9% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.2% | -7.4% | 0.0% | +38.0% |
Valuation Metrics
SKIN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 6.7x trailing earnings, SBC trades at a 82% valuation discount to NPKI's 36.8x P/E. On an enterprise value basis, SBC's 2.9x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $329M | $16M | $1.3B | $118M |
| Enterprise ValueMkt cap + debt − cash | $216M | $21M | $1.3B | $264M |
| Trailing P/EPrice ÷ TTM EPS | 6.65x | -3.29x | 36.75x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.07x | — | 29.34x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 2.92x | — | 18.49x | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 1.60x | 4.70x | 4.71x | 0.39x |
| Price / BookPrice ÷ Book value/share | 1.59x | 0.90x | 3.77x | 2.02x |
| Price / FCFMarket cap ÷ FCF | 19.17x | — | 49.58x | 3.17x |
Profitability & Efficiency
SBC leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-184 for LASE. SBC carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SBC scores 7/9 vs LASE's 1/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +17.5% | -183.5% | +10.3% | -9.4% |
| ROA (TTM)Return on assets | +13.5% | -43.1% | +8.5% | -1.2% |
| ROICReturn on invested capital | +72.3% | -42.1% | +9.9% | -6.8% |
| ROCEReturn on capital employed | +37.9% | -45.9% | +12.7% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 1 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 0.49x | 0.10x | 6.20x |
| Net DebtTotal debt minus cash | -$113M | $4M | $31M | $146M |
| Cash & Equiv.Liquid assets | $125M | $533,871 | $5M | $233M |
| Total DebtShort + long-term debt | $12M | $5M | $37M | $379M |
| Interest CoverageEBIT ÷ Interest expense | 596.05x | -6.60x | 77.08x | 0.81x |
Total Returns (Dividends Reinvested)
NPKI leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NPKI five years ago would be worth $19,150 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, NPKI leads with a +94.9% total return vs LASE's -74.1%. The 3-year compound annual growth rate (CAGR) favors NPKI at 24.2% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -25.9% | -63.8% | +27.6% | -35.0% |
| 1-Year ReturnPast 12 months | +0.3% | -74.1% | +94.9% | -35.9% |
| 3-Year ReturnCumulative with dividends | -68.9% | -76.6% | +91.5% | -91.7% |
| 5-Year ReturnCumulative with dividends | -67.8% | -72.0% | +91.5% | -92.9% |
| 10-Year ReturnCumulative with dividends | -67.8% | -72.0% | +91.5% | -91.6% |
| CAGR (3Y)Annualised 3-year return | -32.2% | -38.4% | +24.2% | -56.4% |
Risk & Volatility
Evenly matched — SBC and NPKI each lead in 1 of 2 comparable metrics.
Risk & Volatility
SBC is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NPKI currently trades 93.5% from its 52-week high vs LASE's 10.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 1.68x | 1.47x | 2.00x |
| 52-Week HighHighest price in past year | $5.75 | $6.77 | $16.50 | $2.69 |
| 52-Week LowLowest price in past year | $2.97 | $0.38 | $7.63 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +55.8% | +10.7% | +93.5% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 29.9 | 38.5 | 56.6 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 87K | 1.9M | 795K | 760K |
Analyst Outlook
LASE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SBC as "Buy", NPKI as "Buy", SKIN as "Hold". Consensus price targets imply 180.4% upside for SBC (target: $9) vs 42.9% for SKIN (target: $1).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Hold |
| Price TargetConsensus 12-month target | $9.00 | — | — | $1.30 |
| # AnalystsCovering analysts | 1 | — | 3 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.7% | 0.0% |
SBC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SKIN leads in 1 (Valuation Metrics). 1 tied.
SBC vs LASE vs NPKI vs SKIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SBC or LASE or NPKI or SKIN a better buy right now?
For growth investors, NPK International Inc.
(NPKI) is the stronger pick with 27. 4% revenue growth year-over-year, versus -13. 3% for Laser Photonics Corporation (LASE). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SBC or LASE or NPKI or SKIN?
On trailing P/E, SBC Medical Group Holdings Incorporated (SBC) is the cheapest at 6.
7x versus NPK International Inc. at 36. 8x. On forward P/E, SBC Medical Group Holdings Incorporated is actually cheaper at 7. 1x.
03Which is the better long-term investment — SBC or LASE or NPKI or SKIN?
Over the past 5 years, NPK International Inc.
(NPKI) delivered a total return of +91. 5%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: NPKI returned +91. 5% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SBC or LASE or NPKI or SKIN?
By beta (market sensitivity over 5 years), SBC Medical Group Holdings Incorporated (SBC) is the lower-risk stock at 0.
76β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 163% more volatile than SBC relative to the S&P 500. On balance sheet safety, SBC Medical Group Holdings Incorporated (SBC) carries a lower debt/equity ratio of 6% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SBC or LASE or NPKI or SKIN?
By revenue growth (latest reported year), NPK International Inc.
(NPKI) is pulling ahead at 27. 4% versus -13. 3% for Laser Photonics Corporation (LASE). On earnings-per-share growth, the picture is similar: NPK International Inc. grew EPS 124. 0% year-over-year, compared to 15. 5% for SBC Medical Group Holdings Incorporated. Over a 3-year CAGR, NPKI leads at 12. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SBC or LASE or NPKI or SKIN?
SBC Medical Group Holdings Incorporated (SBC) is the more profitable company, earning 22.
7% net margin versus -73. 8% for Laser Photonics Corporation — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -189. 3% for LASE. At the gross margin level — before operating expenses — SBC leads at 76. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SBC or LASE or NPKI or SKIN more undervalued right now?
On forward earnings alone, SBC Medical Group Holdings Incorporated (SBC) trades at 7.
1x forward P/E versus 29. 3x for NPK International Inc. — 22. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBC: 180. 4% to $9. 00.
08Which pays a better dividend — SBC or LASE or NPKI or SKIN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SBC or LASE or NPKI or SKIN better for a retirement portfolio?
For long-horizon retirement investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
76)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SBC: -67. 8%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SBC and LASE and NPKI and SKIN?
These companies operate in different sectors (SBC (Industrials) and LASE (Industrials) and NPKI (Energy) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SBC is a small-cap deep-value stock; LASE is a small-cap quality compounder stock; NPKI is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.